LEO Pharma A/S develops, manufactures, and markets pharmaceuticals products. The Company provides dermatology and critical care products for the treatment of psoriasis, atopic dermatitis, eczema, skin infections, actinic keratosis, acne, non-melanoma skin cancer, and thrombosis. LEO Pharma serves customers worldwide.
In India, the Pharmaceutical business of LEO Pharma A/S is focused on Topical Spray for Biologically Active Vitamin D, Treatment of Alopecia Areata, Benzodioxole Heterocyclic Compounds, Homopiperazine Derivatives.
LEO Pharma A/S filed patent application numbered 10596/CHENP/2012 that is titled BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS. This patent application has been granted as Patent Number 312656.
The invention covers Chemical compounds. This invention relates to compounds of the general formula (I);
wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, -S(O)- and – S(0)2-; R3 is -CHF2, -CF3, -OCHF2, -OCF3, -SCHF2 or -SCF3; X is a bond, -CH2-, or -NH-; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; and R4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy; or pharmaceutically acceptable salts, hydrates or solvates thereof, have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the Claim(s) (1-21) are statutorily non-patentable and are mere new form of known compound.
As a response, the Applicant humbly submits that the compound of general formula IIb as disclosed in the present invention is novel and has not been disclosed anywhere before. The same has also been acknowledged by the examiner of Patents in first examination report.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
